{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a
to a specific field?
Status:
Investigational
Source:
INN:moxaprindine [INN]
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Moxaprindine is a antiarrhythmic drug for the treatment of ventricular arrhythmias patented by Manufacture de Produits Pharmaceutiques A. Christiaens, S. A. In clinical studies Moxaprindine shows high efficacy in suppressing ventricular arrhythmias occurring before, during and after maximal exercise stress testing. This effect was obtained both in subjects with clinically normal hearts and in a limited number of patients with ischemic heart disease.
Status:
Investigational
Source:
NCT02743026: Not Applicable Interventional Completed HIV
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01452919: Phase 3 Interventional Completed Schizophrenia
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
LY404039 [(-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid] is an agonist of orthosteric metabotropic glutamate receptor (mGluR)2/3. In addition, it acts as an agonist at dopamine D2 receptors. LY404039 demonstrated broad antipsychotic and anxiolytic efficacy across multiple animal models. LY-2140023 is a methionine amide prodrug of LY-404039 being developed by Eli Lilly & Co for the potential oral treatment of schizophrenia.
Status:
Investigational
Source:
NCT03830684: Phase 2 Interventional Unknown status Influenza
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Baicalein is a flavonoid is a component of the traditional herbal remedy known as Chinese skullcap (or Huang Qin), possesses various biological activities. Baicalein is a neuroprotective agent, which is studied in phase I for the treatment of Parkinson’s disease. By modulating of γ-aminobutyric acid (GABA) type A receptors, baicalein promotes nonamyloidogenic processing of amyloid precursor protein (APP), thereby reducing β-amyloid (Aβ) production and improving cognitive performance in models of Alzheimer's disease. By inhibiting the NF-κB signaling pathway, baicalein suppressed cancer cells proliferation and suppressed the viability of human endometrial stromal cells, thus it may provide a novel treatment option for endometriosis. Besides, this compound was evaluated for its ability to inhibit the influenza virus. Experiments on mice have shown that baicalein showed significant effects in preventing death, increasing the mean time to death and reducing the lung virus titer in a dose-dependent manner.
Status:
Investigational
Source:
NCT02842944: Not Applicable Interventional Unknown status Respiration, Artificial
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Primisulfuron-methyl is a urea herbicide that is used on crop and non- crop areas for the control of grass weeds and many kinds of broad-leaved weeds. Primisulfuron-methyl is a selective postemergence systemic herbicide that is rapidly absorbed by plants and transported throughout the plant roots and foliage. The herbicide works by blocking cell growth in the active growing regions of the plant. Primisulfuron-methyl is practically non-toxic by ingestion, with a reported oral LD50 of greater than 5050 mg/kg in rats. Primisulfuron-methyl is practically nontoxic to wildfowl. Both bobwhite quail and mallard ducks show a high tolerance for the compound. Primisulfuron-methyl is of low to moderate persistence in the soil environment, with a field half-life of from 4 to 60 days. A representative value is estimated to be about 30 days.
Status:
Investigational
Source:
NCT01294202: Phase 2 Interventional Completed Gastrointestinal Stromal Tumor (GIST)
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Onalespib (AT13387; (2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-methyl-piperazin-1-ylmethyl)-1,3-dihydro-isoindol-2-yl] methanone, l-lactic acid salt), is wholly owned by Astex, a novel, high-affinity HSP90 inhibitor, which is currently being clinically tested, has shown activity against a wide array of tumor cell lines, including lung cancer cell lines. As a targeted inhibitor of Hsp90, onalespib has the potential to control the proliferation of multiple solid tumors and hematological malignancies where uncontrolled cell growth is dependent on the interaction between Hsp90 and its client proteins. Astex is pursuing an approach based on the observation that addition of onalespib to a molecularly targeted agent may delay the emergence of resistance to the agent, and hence prolong the window of therapeutic benefit. Onalespib is currently being evaluated via a CRADA with the National Cancer Institute (NCI) in various tumor types, and in a Phase 1/2 clinical study in combination with AT7519, Astex CDK inhibitor.
Status:
Investigational
Source:
NCT01137526: Phase 2 Interventional Completed Alzheimer's Disease
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Moxilubant is an orally active leukotriene B4 antagonist patented by Ciba-Geigy A.-G. and studied for psoriasis, rheumatoid arthritis, and chronic obstructive pulmonary disease treatment. Moxilubant inhibits LTB4 signaling with a potency of 2–4 nM. In a phase 1 study in 10 healthy volunteers, Moxilubant was administered orally once or twice daily for 7 days at doses ranging from 100 to 500 mg. At dose levels of 150 mg and above, LTB4 pathway inhibition reached at least 75%. At doses of 300 mg and above, pathway inhibition reached 100%. A Phase 2 study was conducted in 24 patients with COPD treated with 240 mg/day Moxilubant for 4 weeks. In this study, there were no changes in sputum cell counts or biomarkers or in spirometry measures, even though plasma levels of Moxilubant were sufficient to significantly reduce pathway signaling.
Status:
Investigational
Source:
NCT00443924: Phase 1 Interventional Completed Ocular Hypertension
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Latrunculin B originates from Latrunculia (now Negombata) magnifica, a sponge from the Red Sea. Latrunculin B inhibits the assembly of actin microfilaments by 1:1 molecular binding of free actin monomers in the cell cytoplasm. It may be a potential therapeutic agent for glaucoma. Latrunculin B induced destabilization of the actin microfilament and apoptosis in a dose-dependent manner, as demonstrated by morphological changes and nuclear condensation in the PC3M cells. In addition, it resulted in an increase in the levels of gamma-H2AX recruitment, implicating the induction of DNA damage, including double-strand breaks. Induction of Bax, with little effect on Bcl-2 expression, indicated that actin disruption causes apoptosis through activation of Bax signaling in PC3M cells. This data might helps to develop the strategy for actin-based anticancer chemotherapy against highly metastatic prostate cancer.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
FLUCINDOLE, a cyclindole derivative, is an antipsychotic agent with tricyclic structure.
